Progeneer announced on the 28th that it has signed a Material Transfer Agreement with FUJIFILM Pharmaceuticals U.S.A. Inc. (President: Susumu Shimoyama), Fujifilm's global center for drug development located in the United States, to explore the synergistic effects of both companies' compounds.
Under this agreement, Progeneer will receive the liposomal chemotherapy agents FF-10832 and FF-10850, which are in clinical trial phases, from FFPU to explore the combined effects with Progeneer's immunomodulator, 'ProLNG-001', which is currently under development.
According to Progeneer, ProLNG-001 was initially developed as a vaccine adjuvant but was found to have high efficacy and immune acquisition effects when administered with an in-situ vaccine, a therapeutic agent inducing cell apoptosis, in non-clinical tumor models. Consequently, the company has recently initiated a GLP toxicity study aiming to enter Phase 1 clinical trials by 2025.

https://www.yakup.com/news/index.html?mode=view&cat=12&nid=291050